Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Outset Medical, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's Tablo products used in dialysis care [1][2]. Summary by Sections Class Period and Allegations - The class period for the lawsuit is from August 1, 2022, to August 7, 2024 [2]. - Allegations include that Outset Medical marketed its Tablo products for uses not approved by the FDA, which could lead to a need for additional regulatory applications [2]. - There is a substantial risk that the company may have to cease sales of Tablo products pending FDA approval for additional indications [2]. - The company reportedly lacked the necessary sales team and processes to effectively ramp up Tablo sales, which would adversely impact revenue growth [2]. - Positive statements made by the defendants regarding the company's business and prospects were claimed to be materially misleading [2]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of October 28, 2024, to potentially become lead plaintiffs [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Outset Medical, Inc. (NASDAQ: OM) securities between August 1, 2022 and August 7, 2024. Outset Medical is a medical technology company. Its primary products are the Tablo series devices used in dialysis care, including the Tablo Hemodialysis System and the TabloCart. For more information, submit a form, email attorney A ...

NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Outset Medical investors who were adversely affected by alleged securities fraud between August 1, 2022 and August 7, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/outset-medical-l ...

NEW YORK, Sept. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM). Shareholders who purchased shares of OM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/outset-medical-loss-submission-form/?id=102423&from=4 CLASS PERIOD: August 1, 2022 t ...

NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- __________________ WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outset Medical, Inc. (NASDAQ: OM) between August 1, 2022 and August 7, 2024, both dates inclusive (the "Class Period"), of the important October 28, 2024 lead plaintiff deadline. SO WHAT: If you purchased Outset Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a cont ...

SAN FRANCISCO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Hagens Berman Outset Medical (NASDAQ: OM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may assist the investigation to contact its attorneys. The litigation focuses on the propriety of Outset Medical's disclosures about its business prospects and operations, specifically those concerning its Tablo Hemodialysis System ("Tablo products"). The company received Section 510(k) clearance f ...

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Outset Medical, Inc. (NASDAQ: OM). Shareholders who purchased shares of OM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/outset-medical-loss-submission-form/?id=101889&from=4 CLASS PERIOD: August 1, 2022 t ...

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Outset Medical investors who were adversely affected by alleged securities fraud between August 1, 2022 and August 7, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/outset-medic ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Outset Medical, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions related to the company's Tablo products used in dialysis care [1][2]. Summary by Sections Class Period and Allegations - The class period for the lawsuit is from August 1, 2022, to August 7, 2024 [2]. - Allegations include that Outset Medical marketed Tablo products for uses not approved by the FDA, which may lead to a need for additional regulatory applications [2]. - There is a substantial risk that the company could cease sales of Tablo products pending FDA approval, and the company lacks the necessary sales team and processes to effectively ramp up sales [2]. - These factors are expected to adversely impact the company's revenue growth and render previous positive statements about the business misleading [2]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of October 28, 2024, to potentially be appointed as lead plaintiffs [3]. - Registration will provide shareholders with updates throughout the lifecycle of the case, and participation incurs no cost or obligation [3]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Outset Medical, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on October 28, 2024 [1]. Group 1: Class Action Details - Investors who purchased Outset Medical securities between August 1, 2022, and August 7, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by October 28, 2024, to represent other class members in the litigation [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Outset Medical made false or misleading statements regarding its Tablo products, including marketing for unapproved uses and lacking the necessary sales infrastructure [5]. - The claims suggest that these misrepresentations led to adverse impacts on Outset Medical's revenue growth and misled investors about the company's business prospects [5].